MediWound (NASDAQ:MDWD) Shares Break Below 50 Day Moving Average – Here’s Why

MediWound Ltd. (NASDAQ:MDWD)’s stock price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $13.21 and traded as low as $12.46. MediWound shares last traded at $12.97, with a volume of 354,543 shares trading hands.

More MediWound News

Investors following MDWD have been watching these news items:

• Positive Sentiment: MediWound said its Phase III VALUE trial of EscharEx® is advancing, with an interim assessment and enrollment completion expected by the end of Q1 2027. Company results and update
• Neutral Sentiment: The company reported a loss of $0.65 per share, narrower than the $0.71 loss analysts expected, but wider than its $0.24 loss a year earlier. The earnings beat offers some support, though the year-over-year deterioration tempers it. Zacks Q3 results
• Negative Sentiment: Third-quarter revenue was $3.57 million, well below the $6.73 million consensus estimate—about a 47% miss. Reports attributed the weakness in part to stalled U.S. government work. Q3 revenue and government work

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on MDWD shares. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 26th. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a report on Wednesday, September 16th. Weiss Ratings cut MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. TD Cowen reiterated a “buy” rating on shares of MediWound in a research note on Thursday, September 24th. Finally, Oppenheimer reissued an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MediWound currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

MediWound Price Performance

The company has a fifty day moving average of $13.21 and a 200 day moving average of $15.08. The firm has a market capitalization of $168.74 million, a P/E ratio of -7.21 and a beta of 0.07.

MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The business had revenue of $3.57 million during the quarter, compared to the consensus estimate of $6.73 million. On average, sell-side analysts forecast that MediWound Ltd. will post -2.37 EPS for the current year.

Insider Activity at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On MediWound

An institutional investor recently raised its stake in MediWound stock. Russell Investments Group Ltd. boosted its position in MediWound Ltd. (NASDAQ:MDWD) by 750.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,494 shares of the biopharmaceutical company’s stock after buying an additional 50,732 shares during the period. Russell Investments Group Ltd. owned approximately 0.44% of MediWound worth $792,000 at the end of the most recent quarter. 46.83% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.